Fortitude Advisory Group L.L.C. raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Rating) by 45.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 134 shares of the company’s stock after buying an additional 42 shares during the quarter. Fortitude Advisory Group L.L.C.’s holdings in IDEXX Laboratories were worth $73,000 as of its most recent SEC filing.
A number of other large investors also recently modified their holdings of IDXX. Norges Bank acquired a new position in shares of IDEXX Laboratories in the fourth quarter valued at $494,883,000. Winslow Capital Management LLC acquired a new position in shares of IDEXX Laboratories in the first quarter valued at $249,875,000. American Century Companies Inc. raised its stake in shares of IDEXX Laboratories by 32.1% in the first quarter. American Century Companies Inc. now owns 1,423,600 shares of the company’s stock valued at $778,795,000 after purchasing an additional 346,118 shares in the last quarter. BlackRock Inc. raised its stake in shares of IDEXX Laboratories by 3.4% in the fourth quarter. BlackRock Inc. now owns 8,990,586 shares of the company’s stock valued at $5,919,940,000 after purchasing an additional 296,552 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of IDEXX Laboratories by 18.9% in the fourth quarter. Alliancebernstein L.P. now owns 1,596,308 shares of the company’s stock valued at $1,051,105,000 after purchasing an additional 254,033 shares in the last quarter. 88.45% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of analysts have weighed in on IDXX shares. Morgan Stanley lowered their price target on IDEXX Laboratories from $603.00 to $573.00 and set an “overweight” rating on the stock in a research report on Thursday, August 4th. StockNews.com upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Monday, September 5th. The Goldman Sachs Group upgraded IDEXX Laboratories from a “neutral” rating to a “buy” rating and lowered their price target for the company from $530.00 to $435.00 in a research report on Thursday, July 21st. Stifel Nicolaus cut IDEXX Laboratories from a “buy” rating to a “hold” rating and set a $415.00 price target on the stock. in a research report on Wednesday, August 3rd. Finally, Atlantic Securities lowered their price target on IDEXX Laboratories from $500.00 to $490.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 3rd. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $483.57.
IDEXX Laboratories Stock Performance
IDEXX Laboratories Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.
- Get a free copy of the StockNews.com research report on IDEXX Laboratories (IDXX)
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
- Why Medical Products Maker Repligen May Be A Potential Buy
- At 10%, Is Arbor Realty Trust Dividend Worth It?
- Investors Should Tune Into RF Industries
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.